Primary testicular lymphoma
- 23 January 2014
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 123 (4), 486-493
- https://doi.org/10.1182/blood-2013-10-530659
Abstract
Primary testicular lymphoma (PTL) is a rare, clinically aggressive form of extranodal lymphoma. The vast majority of cases are histologically diffuse large B-cell lymphoma, but rarer subtypes are clinically important and must be recognized. In this review, we discuss the incidence, clinical presentation, and prognostic factors of PTL and present a summary of the recent advances in our understanding of its pathophysiology, which may account for the characteristic clinical features. Although outcomes for patients with PTL have historically been poor, significant gains have been made with the successive addition of radiotherapy (RT), full-course anthracycline-based chemotherapy, rituximab and central nervous system–directed prophylaxis. We describe the larger retrospective series and prospective clinical trials and critically examine the role of RT. Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 21 days with intrathecal methotrexate and locoregional RT is the current international standard of care, a substantial minority of patients progress, representing an unmet medical need. Finally, we discuss new treatment approaches and recent discoveries that may translate into improved outcomes for patients with PTL.This publication has 88 references indexed in Scilit:
- High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesBlood Cancer Journal, 2013
- Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine ModelsPLOS ONE, 2013
- Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana LinfomiHaematologica, 2013
- Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphomaLeukemia, 2012
- Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018Journal of Clinical Oncology, 2011
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphomaBlood, 2008
- Orbital Infiltration as the First Site of Relapse of Primary Testicular T-cell LymphomaCancer Research and Treatment, 2007
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000